Specialty Pharmas initiation details at Credit Suisse

Credit Suisse initiates the Specialty Pharmas with an Overweight, as they believe that, on a mkt-cap-weighted basis, their coverage universe will outperform the S&P 500 over the next 6-12 months. They initiate Bausch & Lomb (BOL 49.81) with an Underperform and $46 tgt, King Pharma (KG 16.05) with an Underperform and $16 tgt, Medicis Pharma (MRX 23.60) with an Underperform and $24 tgt, and Mylan Labs (MYL 20.59) with an Underperform and $19 tgt. The firm initiates Alcon (ACL 97.41) with a Neutral and $116 tgt, Sepracor (SEPR 56.60) with a Neutral and $65 tgt, TEVA Pharma (TEVA 32.34) with a Neutral and $38 tgt, and Watson Pharma (WPI 23.32) with a Neutral and $27 tgt. Finally the firm initiates Allergan (AGN 103.94) with an Outperform and $123 tgt, BioVail (BVF 21.86) with an Outperform and $31 tgt, Barr Pharma (BRL 48.65) with an Outperform and $65 tgt, Advanced Medical Options (EYE 49.48) with an Outperform and $58 tgt, and Forest Labs (FRX 36.97) with an Outperform and $53 tgt.